Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22117203 | 0.94 | ALDH1A1 (0.33) | TSHRALDH1A1LMNA | |
| SCHEMBL22402371 | 0.80 | TSHR (0.42) | TSHRALDH1A1LMNA | |
| SCHEMBL3431923 | 0.76 | PTGS1 (0.37) | — | |
| SCHEMBL3123097 | 0.74 | TSHR (0.41) | TSHRALDH1A1LMNAABCC4MAPT | |
| SCHEMBL4320779 | 0.74 | TSHR (0.44) | TSHRALDH1A1 | |
| SCHEMBL3431919 | 0.72 | — | — | |
| SCHEMBL1241873 | 0.72 | TSHR (0.46) | TSHRALDH1A1LMNAABCC4MAPT | |
| SCHEMBL22117260 | 0.71 | TSHR (0.37) | TSHRALDH1A1LMNAABCC4MAPT | |
| SCHEMBL22117236 | 0.71 | TSHR (0.37) | TSHRALDH1A1LMNAABCC4MAPT | |
| SCHEMBL733134 | 0.71 | TSHR (0.40) | TSHRALDH1A1LMNAABCC4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220071971-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2022-03-10 | — | — | US | disclosed |
| EP-3898621-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| CN-113227087-A | Macrocyclic compounds and their use in the treatment of disease | 诺华股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| WO-2020128925-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020128925-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220071971-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE | CFTR, PKD1, PKD2 | TSHR 1576/4885ALDH1A1 1333/4885LMNA 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.